In the Claims

1 (currently amended). A peptidomimetic having the structure shown in formula I:



(I)

wherein

R^1 is selected from the group consisting of ~~alkyl,~~ alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with one or more of the following: any halogen, -CN, -COOH, =O, -OH, $-NO_2$, $-NH_2$, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, and heterocycloalkoxycarbonyl;

or a salt thereof.

2 (previously presented). The peptidomimetic according to claim 1, wherein R^1 is aryl optionally substituted with one or more halogen, -CN, $-NO_2$, $-NH_2$, $-CH_3$, or $-OCH_3$.

3 (previously presented). The peptidomimetic according to claim 2, wherein said one or more halogen is, independently, Cl or F.

4 (previously presented). The peptidomimetic according to claim 1, wherein R^1 is phenyl substituted with one or more halogen, -CN, $-NO_2$, $-NH_2$, $-CH_3$, or $-OCH_3$.

5 (previously presented). The peptidomimetic according to claim 4, wherein said one or more halogen is, independently, Cl or F.

6 (previously presented). The peptidomimetic according to claim 1, wherein R^1 is heteroaryl optionally substituted with one or more halogen, -CN, $-NO_2$, $-NH_2$, $-CH_3$, or $-OCH_3$.

7 (previously presented). The peptidomimetic according to claim 6, wherein said one or more halogen is, independently, Cl or F.

8 (previously presented). The peptidomimetic according to claim 1, selected from the group consisting of:



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

and



9 (previously presented). A composition comprising a peptidomimetic of claim 1 in a pharmaceutically acceptable carrier or diluent.

10 (previously presented). A method for inhibiting growth or replication, or inducing apoptosis in a target cell, said method comprising contacting the target cell with a peptidomimetic of claim 1 or a composition of claim 9.

11 (previously presented). The method according to claim 10, wherein said peptidomimetic is selected from the group consisting of:



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

and



12 (previously presented). A method for treating a tumor or an oncological disorder in a human or animal, said method comprising administering an effective amount of a peptidomimetic of claim 1 or a composition of claim 9 to the human or animal.

13 (previously presented). The method according to claim 12, wherein said peptidomimetic is selected from the group consisting of:



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

or



;

and



14 (previously presented). The method according to claim 12, wherein said tumor or oncological disorder is selected from the group consisting of breast, kidney, mouth, larynx, esophagus, stomach, testis, cervix, head, neck, colon, ovary, lung, bladder, skin, muscle, pancreas, prostate, bone, eye, blood cells, and brain.

15 (currently amended). A peptidomimetic having the formula:

$$R^1Y^*L$$

wherein

R^1 is selected from the group consisting of ~~alkyl,~~ alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with one or more of the following: any halogen, -CN, -COOH, =O, -OH, $-NO_2$, $-NH_2$, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, and heterocycloalkoxycarbonyl;

Y* is phosphotyrosine, wherein the aromatic ring of phosphotyrosine can be optionally substituted with any halogen, -OH, $-NO_2$, $-NH_2$, -COOH, alkyl, or alkoxy;

L is leucine, or another non-polar amino acid;

or a salt thereof.

16 (previously presented). The peptidomimetic according to claim 15, wherein L is alanine or valine.

17 (previously presented). The peptidomimetic according to claim 1, wherein the peptidomimetic has the structure:



18 (previously presented). The method according to claim 10, wherein the peptidomimetic has the structure:



19 (previously presented). The method according to claim 12, wherein the peptidomimetic has the structure:



20 (previously presented). The peptidomimetic according to claim 15, wherein said phosphotyrosine is optionally substituted with $-CH_3$ or $-OCH_3$.